Alvotech (NASDAQ:ALVOW – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 9,400 shares, a ...

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its blockbuster growth drugs like Prolia and Xgeva.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

In the short history of biosimilars ... At press time, the FDA had approved three more biosimilars in 2025, two for Prolia (denosumab) and Xgeva (denosumab) and another for NovoLog (insulin aspart).

The cases against Yoon, former Defense Minister Kim Yong-hyun and Noh Sang-won, former commander of the Defense Intelligence Command, were filed with the police in connection with Yoon's short-lived ...